Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

Posted on December 11th, 2019 by

medicine

When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.

(more…)

FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool

Posted on December 3rd, 2019 by

A leading cause of attrition of compounds in drug development, drug-induced liver injury (DILI) is also one of the top causes of drug withdrawals, restrictions and project terminations. DILI results when reactive metabolites – formed when certain orally administered drugs are metabolized in the liver – end up binding to cellular proteins and damaging liver cells.

(more…)

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 by

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

(more…)

How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance

Posted on March 7th, 2019 by

Adverse drug reactions can be costly and cost is just the tip of the iceberg.  This is highlighted by an FDA website which cites troubling statistics such as the 100k deaths and over 2 million serious adverse drug reactions experienced each year…

(more…)

  1. 1
  2. 2
  3. 3
  4. 17